The US FDA has extended their emergency use authorization (EUA) for the INDICAID COVID-19 Rapid Antigen Test to cover serial testing for asymptomatic individuals in a recent update.

The update extends the use of INDICAID as a screening test, providing an additional accurate and reliable testing option for schools, workplaces, and communities.

“We welcome the US FDA’s decision to extend the use of INDICAID to asymptomatic serial testing,” says PHASE Scientific Founder and CEO Ricky Chiu. “It busts the myth that antigen tests could only detect symptomatic patients and shows that high-quality antigen tests can be sensitive, accurate, and reliable to be used for population screening.”
FDA EUA Update